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Abstract
Background: Evidence suggests there are inconsistencies in patient-reported outcome (PRO) assessment and reporting in
clinical trials, which may limit the use of these data to inform patient care. For trials with a PRO endpoint, routine inclusion
of key PRO information in the protocol may help improve trial conduct and the reporting and appraisal of PRO results;
however, it is currently unclear exactly what PRO-specific information should be included. The aim of this review was to
summarize the current PRO-specific guidance for clinical trial protocol developers.
Methods and Findings: We searched the MEDLINE, EMBASE, CINHAL and Cochrane Library databases (inception to
February 2013) for PRO-specific guidance regarding trial protocol development. Further guidance documents were
identified via Google, Google scholar, requests to members of the UK Clinical Research Collaboration registered clinical trials
units and international experts. Two independent investigators undertook title/abstract screening, full text review and data
extraction, with a third involved in the event of disagreement. 21,175 citations were screened and 54 met the inclusion
criteria. Guidance documents were difficult to access: electronic database searches identified just 8 documents, with the
remaining 46 sourced elsewhere (5 from citation tracking, 27 from hand searching, 7 from the grey literature review and 7
from experts). 162 unique PRO-specific protocol recommendations were extracted from included documents. A further 10
PRO recommendations were identified relating to supporting trial documentation. Only 5/162 (3%) recommendations
appeared in $50% of guidance documents reviewed, indicating a lack of consistency.
Conclusions: PRO-specific protocol guidelines were difficult to access, lacked consistency and may be challenging to
implement in practice. There is a need to develop easily accessible consensus-driven PRO protocol guidance. Guidance
should be aimed at ensuring key PRO information is routinely included in appropriate trial protocols, in order to facilitate
rigorous collection/reporting of PRO data, to effectively inform patient care.
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Introduction
Patient-reported outcomes (PROs), including health-related
quality of life (HRQL), symptoms such as pain or fatigue, and
health utility, are increasingly assessed in clinical trials as a
measure of effectiveness.[1–3] PRO trial data may be used to
inform clinical care and decision-making, predict long-term
outcomes and influence health-policy; but to do so, as with any
trial outcome, they must be collected with rigor. Unfortunately,
evidence shows that the quality of PRO data can be undermined
in some trials by inconsistencies in data collection [4] and, in
particular, by high rates of missing data [5]; this adversely affects
the integrity and usefulness of such data in clinical practice.
To help ensure optimal PRO data collection, PRO-specific
components should be considered during clinical trial design and
clearly documented in the trial protocol. [6,7] The trial protocol is
the cornerstone of a well-conducted trial, and should provide
specific instruction on how to conduct all aspects of the study. [8]
The protocol also allows external funding bodies, regulators,
research ethics committees, journal editors, health care providers,
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e110216
systematic reviewers and policy makers to evaluate the design and
methods. [6] Despite the importance of PROs, recent data
suggests that some trial staff feel protocols provide little guidance
regarding PRO-specific aspects of the trial, leading to ambiguity
and the potential for significant inconsistency in the way PRO data
are gathered, analysed, acted upon, and reported. [4,9,10].
The recent publication of the SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) guidance aims to
promote the inclusion of important general methodological
components in trial protocols [6]; however, it does not provide
specific guidance related to PROs. It is currently unclear exactly
what PRO-specific information should be included in trial
protocols. The aim of this systematic review was to summarize
current PRO-specific guidance for clinical trial protocol develop-
ers.
Methods
Ethics
This study received ethical approval from the University of
Birmingham ethical review board (ERN_13-0047).
This review was conducted according to PRISMA guidelines
(Checklist S1) [11] and a protocol is available. [12] Given the
methodological focus of the review this was not registered with
PROSPERO at http://www.crd.york.ac.uk/PROSPERO/.
Eligibility criteria
Papers were deemed eligible if they contained guidance (in the
form of advice or formal recommendations) and/or a checklist on
PRO related trial protocol content. As PROs is an ‘umbrella term’
papers including protocol guidance relating to specific types of
PRO (such as HRQL) were also deemed eligible.
Information Sources and Search Strategy
The MEDLINE (Ovid), EMBASE, CINHAL and Cochrane
Library databases were searched from inception to February 2013
(electronic search strategies are presented in full in Appendix S1).
Other relevant articles were identified via two Internet search
engines (Google and Google Scholar) using the key words ‘Patient-
Reported Outcomes’ or ‘Health-Related Quality of Life’ in
combination with ‘Guidance’, ‘Guidelines’ or ‘Checklist’. Only
the first 30 results (3 pages) of each search were reviewed as article
relevance diminishes substantially with each page of results. [13]
In addition, an international advisory group (MB, AG, JB, RMB
and MK) were consulted via email to identify additional ‘grey
literature’ directly relevant to the research question. Finally, PRO
guidance/checklists and Standard Operating Procedures (SOPs)
were requested from all members of the UK Clinical Research
Collaboration registered clinical trials units (UK CRC-CTU) via
email, with one follow up reminder. All citations were downloaded
into Endnote software version X7 and duplicates deleted. Records
were then screened by title/abstract before full-text articles/
documents were retrieved for eligibility evaluation. Remaining
articles were subject to a citation search before a final hand-search
of all reference lists.
Guidance selection
Papers and other guidance documents were deemed eligible if
they provided guidance (advice or formal recommendations) and/
or a checklist describing key PRO-specific information that should
be specified in clinical trial protocols. Non-English papers were
screened by language specialists in the School of Health and
Population Sciences, University of Birmingham. When more than
one edition of a book was available, the latest edition was screened.
Data Extraction
Two reviewers (HDu and AG) independently screened the titles
and abstracts of all citations. Full text versions of potentially
eligible documents were independently reviewed (HDu and AG)
with uncertainties resolved through discussion with a third
investigator (MC/DK). Two investigators (MC and DK), inde-
pendently and in duplicate, extracted both the publication details
and all PRO-specific protocol recommendations from the final
included documents. Data were extracted into Excel on pre-
specified forms to capture: publication source, year of publication,
clinical and regulatory focus. Each recommendation was identified
through independent review by MC and DK and iteratively added
to the spreadsheet following checks for consistency.
Both explicit (‘stated clearly and in detail, leaving no room for
confusion or doubt’ [14]) and implicit (‘suggested though not
directly expressed’ [14]) recommendations for PRO related
protocol content were extracted. Explicit recommendations
specifically stated that an item of PRO information should be
included in the trial protocol. Implicit recommendations described
important PRO trial design issues, and were written in such a way
as to suggest items should be included in the protocol – without
specifically stating so.
Summary of Guidance
For ease of interpretation, PRO protocol recommendations
were extracted and grouped as per SPIRIT guidance headings. [6]
Duplicate recommendations within each of these sections were
identified by MC and DK, and were merged where necessary
following discussion with the international advisory group. The
proportion of guidance documents associated with each recom-
mendation was identified. To assess general trends in guidance
over time, the proportion of guidance documents per recommen-
dation was analysed retrospectively over 5 year time periods.
Results
Selection of Guidance Documents
The literature search yielded 21,175 unique references.
Following application of the inclusion criteria, 54 guidance
documents[1,15–67] were included in the review (Figure 1). DK
and MC independently included 53 of the 54 articles. One paper
was initially excluded by MC but later included following
discussion by the research team. [52] Of the 54 included
documents, 8 were identified from searches of electronic
databases, 5 from citation tracking, 27 from hand searching the
reference lists of included articles, 7 from the grey literature review
and 7 from expert recommendations.
Guidance Characteristics
Document characteristics are summarised in Table 1. The
included materials dated from 1989 to 2013 and included 42
journal articles, 5 books and 7 organizational guideline documents,
with the majority focused on HRQL/PRO assessment in cancer
trials (n = 35, 64.8%) and written from a non-regulatory perspec-
tive (n = 44, 81.5%).
PRO Protocol Guidance
The included guidance documents contained 162 unique
recommendations regarding PRO study design/conduct informa-
tion that should be included in trial protocols. There was
disagreement between data extractors on the inclusion of 10 items
(6.2%), 6 of these items were included following discussion by the
team, whilst 4 were felt to be duplicates of existing items. Of the
162 included items, 134 recommendations were explicit (e.g. ‘All
Systematic Review of PRO Protocol Guidance
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analyses should be clearly defined a priori in the research protocol’
[41]), and 28 were implicit (e.g. ‘…investigators need to provide a
rationale for the selection of a particular HRQL instrument’ [46]).
Protocol recommendations are summarised in Table 2 and
presented in full in Appendix S2; in both places, they are grouped
under SPIRIT guidance headings, with additional subheadings
used to organise content. In addition, 10 PRO recommendations
were related to other supporting trial documentation (Appendix
S3).
Administrative information
There were n= 4 recommendations regarding trial administra-
tion, which centred around identifying the roles and responsibil-
ities of PRO personnel and ranged from advocating involvement
of the research nurse in PRO protocol development, to providing
the contact details of the Quality of Life (QOL) sub-study
coordinator where appropriate.
Introduction: Background, rationale, and objectives/
hypotheses
Eleven unique recommendations related to the inclusion of
PROs in the introductory sections of the protocol. These focused
on aspects surrounding: PRO specific background information
(n = 2), for instance, the need to describe the PRO population of
interest; specification of the PRO rationale (n = 5), for example,
justifying the relevance of PRO assessment in the disease and
population under investigation; or outlining the PRO hypothesis
and objectives (n = 4).
Methods: Participants, interventions and outcomes
There were n= 25 unique recommendations within this section,
focused on a number of areas, including: the PRO study setting
(n = 1), the PRO-specific eligibility criteria (n = 3), the need to
specify the PRO as an endpoint (n = 5), the PRO-specific sample
size (n = 2) and blinding considerations (n = 2). Twelve different
recommendations related to timing of the PRO assessment,
ranging from: including PRO assessment timings in the main
protocol assessment schedule and specifying time windows, to
justifying timings according to the study research questions, length
of recall of the questionnaire, the natural history of the disease
under study, and any planned analysis.
Methods: assignment of interventions
There were no PRO-specific recommendations identified under
this heading.
Methods: Data Collection, management and analysis
Ninety-four recommendations related to PRO-specific protocol
guidance for data collection, management and analysis. These
focused on data collection aspects including: identification/
description of the PRO instrument (n = 4), for instance, the need
to outline the questionnaire domains and number of items;
justifying the choice of instrument (n = 13), for example, the
Figure 1. Search results flow diagram.
doi:10.1371/journal.pone.0110216.g001
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Table 1. Guidance Document Characteristics.
Authors Year
Clinical area in
which guidance
is focused.
PRO Protocol
Checklist provided
Regulatory
Focus* Source
Moinpour et al. [15] 1989 Oncology Journal of the National Cancer Institute
Schron & Schumaker [16] 1992 Cardiovascular Progress in cardiovascular Nursing
Gotay et al. [17] 1992a Oncology Journal of the National cancer Institute
Osoba [18] 1992 Oncology Yes Quality of Life Research
Gotay et al. [19] 1992b Oncology Oncology
Nayfield et al. [20] 1992 Oncology Quality of Life Research
Sadura et al. [21] 1992 Oncology Journal of the National Cancer Institute
Hayden et al. [22] 1993 Oncology Oncology Nursing Forum
Cella et al. [23] 1993 General Quality of Life research
Spilker [24] 1996 General Book (Chapters 45 and 72)
Molin & Arrigo [25] 1995 Oncology Yes European Journal of Cancer
Fayers et al. [26] 1997 Oncology Yes European Journal Cancer
Kiebert [27] 1997 Oncology Yes European Journal of Cancer
Bernhard et al. [28] 1998a Oncology Statistics in medicine
Bernhard et al. [29] 1998b Oncology Statistics in medicine
Osoba [30] 1998 Oncology Statistics in Medicine
Simes et al. [31] 1998 Oncology Statistics in medicine
Moinpour & Lovato [32] 1998 Oncology Statistics in Medicine
Brooks et al. [33] 1998 Cardiovascular Medical Care
Leidy et al. [34] 1999 General Yes Value in Health
Osoba [35] 1999 Oncology European Journal of Cancer
de Haes et al. [36] 2000 Oncology European Journal Cancer
Revicki et al. [37] 2000 General Yes Quality of life Research
Bottomley [38] 2001 Oncology Applied Clinical Trials
Hakamies-Blomqvist et al. [39] 2001 Oncology Journal of Advanced Nursing
Santanello et al. [40] 2002 General Yes Value in Health
Chassany et al. [41] 2002 General Yes Yes Drug Information Journal
EORTC QLG [42] 2002 Oncology Guidance document
Movsas [43] 2003 Oncology Seminars in Radiation Oncology
Calvert & Freemantle [44] 2004 General Yes Journal of Clinical Pharmacy and Therapeutics
Wiklund [45] 2004 General Yes Yes Fundamental & Clinical Pharmacology
Buchanan et al. [46] 2005 Oncology Journal of Clinical Oncology
Fayers & Hays [47] 2005 General Book (Chapter 3.2)
Lipscomb [48] 2005 Oncology Book (Fairclough Chapter)
Avery & Blazeby [49] 2006 Oncology World Journal of Surgery
TRoG [50] 2007 Oncology Policy document
Ganz & Gotay [51] 2007 Oncology Journal of Clinical Oncology
Lipscomb et al. [52] 2007 Oncology Journal of Clinical Oncology
Land et al. [53] 2007 Oncology Journal of Clinical Oncology
Patrick et al. [54] 2007 General Yes Value in Health
Sloan et al. [55] 2007 General Yes Value in Health
Revicki et al. [56] 2007 General Yes Value in Health
Fayers & Machin [57] 2007 General Yes Book
FDA [1] 2009 General Yes Guidance document
Fairclough [58] 2010 General Yes Book
Hao [59] 2010 Oncology Yes Expert Reviews
NCIC CTG [60] 2010 Oncology Yes Guidance document
Basch et al. [61] 2011 Oncology Guidance document
Systematic Review of PRO Protocol Guidance
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importance of referencing the validity, reliability and responsive-
ness of the tool; detailing the data collection plan (n= 10), for
example, stating who should administer the questionnaire; and
describing the data collection/training guidelines (n = 16) (e.g.
outlining the certification process for staff involved in PRO
assessment) and plans to minimise missing data (n = 19) for
example specifying who would check questionnaires for missing
data. There were n= 7 recommendations concerning PRO
specific quality assurance, ranging from the inclusion of guidance
for data entry coding decisions regarding missing or ambiguous
responses; to specifying procedures for a central PRO data
monitoring system aimed at identifying and rectifying potential
data collection problems. Finally, n = 13 recommendations
focused on PRO analysis, specifically: the PRO-specific compo-
nents of the statistical analysis plan (n= 13), for instance, the need
to include an a priori estimation of expected change in PRO score;
plans to address multiple hypothesis testing (n = 2), such as pre-
specification of sequence of testing; defining clinical significance
(n = 6), for example, describing and justifying the minimal
clinically important difference/change); and specifying methods
to deal with missing PRO data (n = 4), for instance, defining
proposed sensitivity analyses for imputation methods.
Methods: Monitoring
There were four recommendations regarding PRO specific trial
monitoring, ranging from the need to define the role of the Data
Monitoring Committee in relation to PROs, to the inclusion of a
plan to manage PRO Alerts.
Ethics and Dissemination
There were n= 3 recommendations focused on PRO-specific
consent information, for example, the need to include information
for patients regarding who should be contacted for help with
completing the PRO questionnaire. Two recommendations
addressed PRO specific confidentiality issues, such as the need
to specify whether QOL data will be used to influence patient
management. Two recommendations focused on the need to
include PRO-specific dissemination plans, through both peer-
reviewed scientific publication and direct participant contact.
Appendices
Fourteen recommendations focused on the inclusion of relevant
PRO documents as protocol appendices, including: a copy of the
PRO questionnaire(s), sample patient information and consent
materials containing PRO information and a PRO-specific
administration flow chart/checklist.
Other Trial Documentation
Ten recommendations focused on PRO information that should
be included in protocol-related trial documents such as Standard
Operating Procedures (SOPs), Case Report Forms (CRFs) or
training manuals (Appendix S3).
Time trends and Common Recommendations
The availability of PRO-specific guidance over time is shown in
Figure 2. The data suggest that there has been consistent
publication of PRO protocol guidance, across all areas, over the
last 25 years (Table 3). In addition, over 75% of recommendations
extracted for this study have been available for at least 10 years.
Only 3% of recommendations appeared in more than half of
the documents included in the study, highlighting a lack of
consistency in the PRO guidance literature reviewed (Table 2).
These included (in order of frequency): the need to specify the
timing of QOL assessment, the provision of PRO data collection
guidelines and/or a training plan, specification (and justification)
for the chosen PRO questionnaire, routine inclusion of a priori
defined PRO analyses plans and specifying a named person within
the trial with responsibility for overseeing QOL assessment.
Discussion
Summary of Findings
Our review is the first to summarise the current PRO-specific
guidance for clinical trial protocol developers. In total we
identified 54 guidance documents[1,15–67], which provided 162
recommendations regarding PRO-specific information that should
be included in protocols containing a PRO endpoint.
Unfortunately, although PRO protocol guidance has been in
existence for over 25 years, our findings suggest it remains difficult
to implement in practice. First, with the exception of 8
publications[16,22,39–41,59,62,63] sourced via electronic data-
base searches, the guidance literature was particularly difficult to
access. The remaining 46 documents, which provided more than
half (56.7%) of all PRO protocol recommendations, were obtained
via citation tracking, hand-searching reference lists of included
articles, grey literature review and expert contact. It is unlikely that
protocol developers would have the time or resources to carry out
such a comprehensive search. As such, developers may be reliant
on a small proportion of guidance documents available via easily
accessible scientific databases. This is problematic, as these
publications provide relatively little coverage of the current PRO
protocol recommendations in circulation. As our findings show,
recommendations are spread over a wide variety of sources, thus,
over reliance on a small number of guidance documents may
Table 1. Cont.
Authors Year
Clinical area in
which guidance
is focused.
PRO Protocol
Checklist provided
Regulatory
Focus* Source
King [66] 2011 Oncology Yes Web-based guidance document
Efficace & Taphoorn [62] 2012 Oncology Journal of Neurooncology
Jensen et al. [63] 2012 Oncology Clinical Investigation
Novik et al. [64] 2012 Haematology Guidance document
Macefield et al. [65] 2013 Oncology British Journal of Surgery
Kyte et al. [67] 2013 General JAMA
*protocol guidance makes reference to the FDA or EMA.
doi:10.1371/journal.pone.0110216.t001
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Table 2. Recommendations appearing in guidance documents.
Recommendation
Number (%) of
Guidance
Documents
ADMINISTRATIVE INFORMATION
Roles & Responsibilities of PRO Personnel
Name the QOL sub-study coordinator - include contact details & institution 2 (3.70)
Research nurses should be involved in protocol development 1 (1.85)
Name the QOL sub-study manager/assistant/officer - include contact details & institution 1 (1.85)
*The involvement of personnel other than those listed in the study should be specified (e.g. Psychologists, social workers etc) 1 (1.85)
INTRODUCTION
Background, Rationale & Objectives
Background PRO-specific information
Describe what is currently known about QOL in this area and explain the gaps in literature 5 (9.26)
*Describe the population of interest 3 (5.56)
PRO-specific rationale
Provide a rationale for measuring QOL- e.g. superior intervention/negative impact of intervention/equivalence 26 (48.15)
Provide a clinical justification for QOL outcome measurement 12 (22.22)
Emphasise importance of QOL assessment to the study 6 (11.11)
Describe why PROs have been included appropriate to the study population, intervention, context objectives and setting 5 (9.26)
Justify the relevance of assessing HRQL for disease and population under investigation 5 (9.26)
Pro-specific hypotheses/objectives
State the QOL hypothesis (and corresponding null hypothesis) and to which outcome the hypothesis relates 23 (42.59)
Identify QOL as an objective/state research objective of HRQL component in relation to dimensions, population and timeframe 22 (40.74)
*Protocols addressing comparative effectiveness research in oncology should include Core Outcome Set symptoms 2 (3.70)
*State whether the study is exploratory or confirmatory. 1 (1.85)
METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES
PRO study setting
*Description and rationale of sampling method (representativeness of population and/or centres, as appropriate) 3 (5.56)
PRO eligibility criteria
Specify if QOL completion is a pre-randomisation eligibility condition 18 (33.33)
*Describe patient eligibility criteria 8 (14.81)
State the inclusion/exclusion criteria for QOL endpoint(s) and analyses (e.g., language/reading requirements) 7 (12.96)
PRO endpoint specification
Define the role of the PRO endpoint (primary, important secondary, exploratory) 14 (25.93)
Specify the timeframe of interest/primary time-point for analysis and the rationale for this 14 (25.93)
Identify QOL as an endpoint 5 (9.26)
Include a conceptual model to define exactly what is being measured,
which domains are covered and what is the intended HRQL claim
5 (9.26)
Describe the constructs used to evaluate the intervention e.g. overall QOL, specific domain, specific symptom 4 (7.41)
Timing of PRO assessments
Specify if baseline assessment is pre-randomisation 19 (35.19)
Specify acceptable time windows for each assessment 16 (29.63)
Specify standardised timing of questionnaire delivery (e.g. before/whilst/after seeing clinician) 16 (29.63)
Include QOL assessment timings in main protocol schedule of assessments 7 (12.96)
Outline standardised order for administration of PRO and clinical assessments 2 (3.70)
Specify which measures will be used at each assessment 1 (1.85)
For open label trials - PRO instruments administered in a clinic visit should be
administered before other clinical assessments or procedures
1 (1.85)
Justification for timing of PRO assessments
Specify the timing of QOL assessments - link to hypotheses 37 (68.52)
Timing should link to research questions, length of recall,
disease/Tx natural history, planned analysis/must be fair for both arms
9 (16.67)
Systematic Review of PRO Protocol Guidance
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Table 2. Cont.
Recommendation
Number (%) of
Guidance
Documents
*Long-term assessments in different treatment groups should be at similar times in relation
to the date of randomisation to avoid bias
3 (5.56)
Other timing information
Minimum assessment at baseline, end of study or at withdrawal 5 (9.26)
Conduct clinical and QOL assessment simultaneously 3 (5.56)
PRO sample size
State the sample size and power requirements in relation to the rationale/objectives/hypothesis 22 (40.74)
If the sample size required for HRQL assessment is substantially less than for primary endpoint an unbiased strategy for selection
of a subset of patients in whom HRQL will be assessed is possible provided that this strategy is clearly
defined and justified in the protocol
4 (7.41)
PROs in relation to blinding
In a blinded study detail the use of PRO administration techniques to minimise the possibility of unblinding 1 (1.85)
Research protocol must specify that interviewers be blind to intervention 1 (1.85)
METHODS: DATA COLLECTION, MANAGEMENT AND ANALYSIS
METHODS: DATA COLLECTION
PRO instrument description
Describe the questionnaire(s) (including, number of items/domains, instrument scaling/scoring, reliability,
content and construct validity, responsiveness, sensitivity, respondent burden,
cultural adaptation/validity, recall period)+/2 validation plan if appropriate
19 (35.19)
Number of items and domains 1 (1.85)
Detail availability of instrument in different languages and their use on the study 1 (1.85)
If appropriate describe administering different QOL forms to subgroups of patients 1 (1.85)
PRO instrument justification
Specify which QOL questionnaires will be used - link to clinical justifications and hypotheses via specific domains/items 32 (59.26)
Specify the HRQL domains the study intervention is expected to effect 17 (31.48)
Reference the validity, reliability and responsiveness of the instrument (may be more succinct with refs if PROM widely used) 14 (25.93)
Outline plans for validation of measurement properties, if appropriate 7 (12.96)
Describe PROM recall period - link to treatment effects 5 (9.26)
Describe questionnaire completion time 4 (7.41)
Selection of questionnaire should be discussed and justified 3 (5.56)
Discuss respondent burden 2 (3.70)
Provide evidence that questionnaire is acceptable to patients 2 (3.70)
International trials should include cultural validity of questionnaire, documentation of any procedures/events
that differ across countries, analysis of cross culture equivalence
2 (3.70)
Specify why the particular questionnaire was chosen in preference to others 1 (1.85)
Provide evidence of measurement equivalence across modes (when mixing modes of PRO data collection) 1 (1.85)
Justify use of questionnaires that take longer than 10 mins to complete (or 20 mins at baseline) 1 (1.85)
PRO data collection plan
Specify how QOL will be assessed - pencil and paper, online, etc 22 (40.74)
Include a pre-specified data collection plan 17 (31.48)
Specify if help and or proxy assessments are permitted (and what level of assistance allowed) 14 (25.93)
Specify where QOL will be assessed - clinic, home, etc 12 (22.22)
Ensure privacy and confidentiality of planned data collection 3 (5.56)
Specify location (e.g. quiet area [an example but not formal recommendation]) 2 (3.70)
Specify how patients will be managed if translations unavailable 1 (1.85)
Specify whether the QOL instrument will be used in other languages – if so, which 1 (1.85)
Substantiate use of proxies (conditions under which proxy permissible) 1 (1.85)
State who will administer the measure (e.g., a physician, nurse etc) 1 (1.85)
PRO data collection guidelines/training infromation
Provide guidelines and/or training plan for PRO data collection 36 (66.67)
Systematic Review of PRO Protocol Guidance
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Table 2. Cont.
Recommendation
Number (%) of
Guidance
Documents
Specify that a named person at each centre (and/or centrally?) be nominated to take responsibility for admin,
collection and checking of QoL forms - specify whether this is or is not the treating clinician
27 (50.00)
Provide instructions on how the patient should complete the form (e.g. without conferring with friends/relatives,
all questions should be answered even if the patient feels them to be irrelevant)
21 (38.89)
Specify procedures for checking questionnaires/prevention of avoidable missing data, who will check form, and how will they deal
with missing questionnaire(s) or items
21 (38.89)
Emphasise importance of good compliance/describe procedures to maximise compliance/minimise missing data 20 (37.04)
Encourage staff to emphasise importance/rationale of QOL assessment to patients 13 (24.07)
Provide reminders to staff to ensure baseline (and follow-up) questionnaires are completed 11 (20.37)
Pre-specified procedures in protocol to avoid/minimise missing data 8 (14.81)
Establish process for PRO assessment at withdrawal for patients that withdraw early from a study 7 (12.96)
Establish process of how to follow patients who go’’off-study’’/"off treatment’’ 7 (12.96)
Provide interviewer training plan/format guidelines for PROs administered by interviewer (plus guidance on recording of interviews) 6 (11.11)
Specify need to ensure backup data collection staff to cover leave/absence 6 (11.11)
A plan should be included in protocol for systematically training and contacting local site personnel to ensure that they understand the
content and importance of collecting PRO data. Ideally coordinated by a lead data manager who monitors patient adherence in real time
and communicates with sites if patient non-adherent
5 (9.26)
Instruct site staff to routinely record (on clinical follow-up form) the reasons for any missing data 4 (7.41)
Explain relevance and emphasise importance of QOL questions that might give rise to problems (e.g. sexual function questions) 4 (7.41)
Detail/outline site-level incentives for good QOL submission rates/data quality and penalties for missing data (as appropriate) 4 (7.41)
Encourage a sympathetic approach to patients who may be feeling particularly ill/show appreciation upon completion 4 (7.41)
Instruct site staff to give patients a full explanation about QoL assessment procedures 3 (5.56)
Instruct site staff to routinely record the source of PRO data in studies that allow proxies 3 (5.56)
Establish back up plans for gathering treatment-related reasons for patients failing to report at scheduled times 3 (5.56)
Instruct site staff to routinely record (on clinical follow-up form) whether QOL assessment completed 2 (3.70)
Instruct site staff to routinely record (on clinical follow-up form) if the patient needed help to complete the questionnaire 2 (3.70)
Provide online training and state in the protocol how this will be accessed 2 (3.70)
Describe process for certification (and re-certification) for staff conducting PRO assessment 2 (3.70)
Specify procedures for continuous QOL instruction/training of staff (needed due to staff changes) 2 (3.70)
Include guidance on discussing importance of PROs with patient 2 (3.70)
Instruct staff regarding the importance of including QOL assessment alongside regular data collection 2 (3.70)
Ensure patients understand the schedule for and importance of follow up visits 2 (3.70)
Encourage the patient to request their QOL forms upon arrival at the clinic 2 (3.70)
Specify procedures for minimising inconsistencies in trial conduct 1 (1.85)
Provide training plan and instructions to patients for self-administered PROs 1 (1.85)
Instruct data collection staff to record the specific mode of PRO administration (in studies with mixed modes of PRO data collection) 1 (1.85)
Provide instructions for clinical investigators regarding patient supervision 1 (1.85)
Include details on data collection and management methods to minimise missing data 1 (1.85)
Strategies for minimising the exclusion of subjects from the trial 1 (1.85)
Plans to avoid/minimise missing data
METHODS: DATA MANAGEMENT
PRO-specific Quality Assurance
Specify procedures for a central PRO data monitoring system (aimed at identifying and rectifying potential data collection problems) 13 (24.07)
Specify plan to monitor compliance 7 (12.96)
Include data collection, data storage and data handling/transmission procedures 5 (9.26)
Specify how an electronic PRO source will be maintained and how investigator will meet regulatory requirements and ensure data
integrity and security
2 (3.70)
Specify procedure for monitoring adherence to timing windows’ 2 (3.70)
Include guidance for data entry on coding responses, missing responses or ambiguous responses 1 (1.85)
Ensure plans for administration consistent with user manual 1 (1.85)
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Table 2. Cont.
Recommendation
Number (%) of
Guidance
Documents
METHODS: DATA ANALYSIS
PRO Statistical Analysis
All analyses should be clearly defined a priori in the protocol 29 (53.70)
Specify ITT or per-protocol analysis. 6 (11.11)
Pre-specify scoring 6 (11.11)
State the anticipated response rate/effect size 4 (7.41)
Specify conditions for positive outcome 3 (5.56)
Ensure plans for scoring are consistent with those used in development 3 (5.56)
Describe methods for scoring endpoints. Where possible, reference scoring manuals for summated scales from questionnaires
(domain-specific and/or total),and methodological papers for composite endpoints (e.g. QTWiST)
2 (3.70)
Explain the assumptions of analyses 1 (1.85)
Include an a priori estimation of expected change in PRO score 1 (1.85)
Include a priori identified summary statistics (as appropriate) 1 (1.85)
Specify minimum amount of QOL data and acceptable degree of timing deviation before compromise of study question 1 (1.85)
Describe approach to controlling for QOL related comorbidity 1 (1.85)
Include appropriate procedures for minimising assessment bias 1 (1.85)
Plans to address multiplicity of PRO data
Plan for multiplicity/controlling type 1 error - summary measures/adjustments 19 (35.19)
Pre-specification of sequence of testing (regulatory trials)/exploratory analyses to control for multiplicity or prespecify domains
for a labelling claim
7 (12.96)
PRO clinical significance
State and justify minimal [clinical] important difference/change 11 (20.37)
Specify the criteria for statistical and clinical significance 4 (7.41)
Define clinical response/method of analysis for response/cumulative distribution function 4 (7.41)
Identify and state score change meaningful to patient 2 (3.70)
Describe QOL responder definitions (size and duration of benefit) where relevant 1 (1.85)
Investigators should indicate how the results will be used. 1 (1.85)
Statisitical methods to deal with missing PRO data
Describe methods for handling missing data 22 (40.74)
Include proposed sensitivity analyses for imputation methods. 6 (11.11)
Include approach to imputation 4 (7.41)
State how missing data will be described 3 (5.56)
MONITORING
PRO data monitoring
Role of DMC and QA in relation to PROs should be defined. 12 (22.22)
PRO alerts
Specify mechanism for alerting clinical staff about symptoms reported by patients that exceed a pre-defined level of severity 2 (3.70)
Provide guidance for staff on where they should refer patients for appropriate help, should completion of the QoL questionnaire
prompt them to seek more information or support
1 (1.85)
Include an a priori plan for consistent/standardised management of PRO alerts that is clearly communicated to all appropriate trial staff 1 (1.85)
ETHICS AND DISSEMINATION
PRO-specific consent information
Explain the QOL assessment procedure within the PIS/consent (including: reasons for evaluating QoL, what it will involve, risks and
benefits, frequency and timing/timeframe, the need to answer all questions, the importance of completing questions without being
influenced by the opinions of others) and, if appropriate, identify if consent to QOL assessment is required for entry into the trial
14 (25.93)
*Describe informed consent procedure. 1 (1.85)
Inform patients who they may contact for help in completing the questionnaire 1 (1.85)
Pro-specific confidentiality procedures
Include guidance on discussing PRO confidentiality with patients (e.g. patients told how their questionnaires will be used) 9 (16.67)
Specify whether QOL forms will be used to influence therapy or patient management (i.e. will clinician have knowledge) 4 (7.41)
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mean important PRO design considerations are overlooked. For
example, even the two publications that provided most recom-
mendations, Chassany [41] and Fairclough [58] (42 recommen-
dations each, 24 shared), provided just 37.04% of the total in
circulation.
Second, developers wishing to use the guidance summarised in
this review face the challenge of trying to incorporate a large
number of recommendations into what is usually a rather limited
amount of space within the protocol. For instance, we identified 94
unique recommendations concerning data collection, manage-
ment and analysis, of which, 19 alone addressed minimising
missing data. Tackling missing PRO data is clearly an important
design consideration since it helps reduce bias and preserves
statistical power [68], however, it may be unrealistic to expect
protocol developers to incorporate all 19 recommendations within
a study protocol.
It is important, therefore, for the scientific community to reach
consensus on the essential PRO protocol content required to
preserve trial integrity; and to provide guidance that is useful in
practice. We advocate the development of consolidated, easily
accessible and internationally endorsed consensus guidelines
addressing this objective. Our review provides a useful starting
point as it presents a comprehensive list of the PRO protocol
guidance currently available, however, it remains unclear at this
stage exactly which of the recommendations identified in this study
should be incorporated into consolidated guidelines. A number of
recommendations are supported by multiple sources and appear to
be underpinned by a clear theoretical justification (for example,
the need to provide a rationale for PRO measurement (recom-
mended in 48.15% of guidance documents)), and may be
promising candidates for inclusion. There were, however, a
number of other recommendations that were less frequently cited,
but still may have important implications for trial conduct,
reporting and the quality of PRO results. For example, referencing
the PRO instrument validity and reliability in the protocol
(recommended in 25.93% of guidance documents) will help ensure
that the psychometric properties of the PRO have been duly
considered during the trial design and will help facilitate later
reporting in accordance with the CONSORT-PRO extension.
[69] In addition, only four publications provided guidance
describing plans for the identification and management of PRO
Alerts, that is: ‘concerning levels of psychological distress or
physical symptoms that may require an immediate response’ [67].
However, evidence suggests that without clear, pre-specified, plans
Table 2. Cont.
Recommendation
Number (%) of
Guidance
Documents
PRO dissemination policy
Include detailed plans for regular feedback to participants via letter/newsletter on QOL aspect of study 2 (3.70)
Include QOL publication policy 1 (1.85)
APPENDICES
PRO components of informed consent materials
A sample PIS and consent form (in which QOL assessment requirements are mentioned) should be included in an appendix of the protocol 8 (14.81)
PIS/Consent form should inform patients what will happen to their completed questionnaires 5 (9.26)
Patients should be provided with QOL information leaflet to take home 2 (3.70)
PRO assessment checklist and/or flowsheet
Include statistical analysis plan in protocol appendix 3 (5.56)
Include a QOL Assessment checklist in a protocol appendix 2 (3.70)
Details about the characteristics of the PRO should be included in an appendix 1 (1.85)
Formal statement on QOL data collection policy should be included in the appendix 1 (1.85)
Checklist should be provided in the protocol 1 (1.85)
Include a QOL patient evaluation flow sheet in the appendix 1 (1.85)
PRO questionnaire
Provide exact version/format of PROM in the protocol within the CRF (or in a separate appendix as appropriate) 10 (18.52)
Present evidence of permission to use QOL questionnaire (where applicable) 2 (3.70)
Include translations of core questionnaire in appendix 1 (1.85)
PROM completion instructions
Ensure clear written patient instructions accompany QOL/PRO questionnaire 9 (16.67)
General Referencing
References should be provided to support key statements 2 (3.70)
GENERAL APPROACH TO PROTOCOL
PRO endpoints should be fully integrated in the trial protocol/data collection 33.33%
PROs should be addressed in a separate chapter in the protocol 7.41%
Relevant sections pertaining to QOL should be identified in the protocol table of contents 1.85%
*These recommendations were made specifically in relation to the PRO component of the study.
doi:10.1371/journal.pone.0110216.t002
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for the management of PRO Alerts, either in the trial protocol or
supporting documentation, variation may occur in their manage-
ment within/across trial sites risking co-intervention bias and
suboptimal patient care. [67].
Consolidated PRO guidance for protocol developers is clearly
necessary, however, our findings also show that guidelines should
be developed using robust consensus methodology to ensure that
the merits of all individual recommendations are carefully
considered prior to selection/rejection. The definitive guidelines
should aim to improve the quality of PRO trial design and
reporting, resulting in more robust PRO trial data that will exert a
greater influence on clinical practice and will provide an improved
information base for future patients. Researchers should be
supported in implementing the guidance through training and
online resources. Furthermore, endorsement by funding bodies
and Institutional Review Boards/Ethical Committees, who review
the content of protocols, and journal editors, who are responsible
for their publication, is important to ensure widespread adoption.
Strengths and Limitations
Our review has for the first time collated and summarised the
existing PRO guidance available for protocol developers using
systematic methods and multiple reviewers. A limitation of our
approach is that the PRO item categorisation and indexing
employed during our analysis is influenced by reviewer interpre-
tation. Also, publications included in the study had to provide
guidance on PRO-protocol content; however, such guidance was
not always the main focus or aim of some of the included articles.
Again, the interpretation of the reviewer may subtly alter the
original meaning of the text drawn from such material. The use of
independent dual data extraction by 2 investigators (with a third to
mediate) sought to reduce these effects, however, they remain a
legitimate concern. Furthermore no formal quality appraisal was
undertaken given the diverse nature of the guidance documents.
Relevant PRO guidance literature was difficult to source and
appeared to be particularly poorly indexed. Whilst we employed a
number of resources to comprehensively search the literature
(including electronic databases, citation tracking and hand
searching, internet search engines and expert contact) further
PRO guidance probably exists that was not included in our study,
such as disease specific documents citing EMA and FDA guidance
included in our review. Consideration of alternative search
strategies, such as ‘citation pearl methodology’ [70], may have
further increased the comprehensiveness of our review. The
International Society for Quality of Life Research Best Practice for
PROs in Trials Taskforce (Co-chaired by authors, MC, MK and
MB) is leading work in this area and would value the identification
of further grey literature across a range of clinical settings on this
Figure 2. PRO protocol guidance trends over time.
doi:10.1371/journal.pone.0110216.g002
Table 3. PRO protocol guidance over time.
Time Period N (%) of new PRO Protocol Recommendations
1989–1993 70 (43.21)
1994–1999 30 (18.52)
1999–2003 23 (14.20)
2004–2008 9 (5.56)
2009–2013 30 (18.52)
doi:10.1371/journal.pone.0110216.t003
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topic by interested readers to inform future guideline development.
A further limitation is that most of the international advisory
group work in an oncology setting therefore are likely to have
greater knowledge of grey literature in this field. However,
oncologists have routinely used PROs for many years and as such
we may anticipate more literature in this clinical area.
Conclusion
PRO-specific protocol guidance is difficult to access, lacks
consistency and is unwieldy; with over 160 recommendations
spread across 54 different publications. It is therefore extremely
challenging to implement in practice. There is a need to develop
easily accessible consolidated, and consensus-driven, PRO proto-
col guidelines. Guidance should aim to ensure key PRO
information is routinely included in trial protocols with a PRO
endpoint, in order to facilitate the rigorous collection and
reporting of PRO data, thus maximising its capacity to effectively
inform patient care.
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